European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy
- PMID: 27349614
- DOI: 10.1016/j.eururo.2016.06.009
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy
Abstract
The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.
Keywords: Cabozantinib; European Association of Urology; Guidelines; Nivolumab; Renal cancer.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources